Eli Lilly CEO on Antibody Trial’s Finish; CEOs Get Out the Vote

The National Institutes of Health has halted one of Eli Lilly’s coronavirus antibody trials, having found that the combination of Lilly’s antibody drug and Gilead’s remdesivir does not result in a marked improvement in hospitalized Covid-19 patients. Eli Lilly CEO David Ricks discusses what’s next for the antibody that’s proven successful in treating milder Covid cases, and he addresses the company’s third quarter financials. CNBC’s All America Survey reveals that while Joe Biden is leading President Trump in the election polls, both candidates must now rely on niche populations for victory. Senior Economics Reporter Steve Liesman unpacks the survey findings and shares which voting groups are crucial to which contender. Boston Consulting Group CEO Rich Lesser shares what c-suites are doing to encourage employee voting, and discusses how American CEOs may think about democracy going forward. Plus, the tech industry has thrown $200 million behind a campaign for California voters to support Proposition 22, the legislation that could preserve independent contractor status for gig economy workers.